News Image

Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

Provided By PR Newswire

Last update: Jul 31, 2025

BAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis efforts for Frenova's transformative My ReasonĀ® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to better understand kidney, cardiovascular, and metabolic diseases while driving advancements in precision medicine for patients worldwide.

Read more at prnewswire.com

AZENTA INC

NASDAQ:AZTA (10/10/2025, 9:11:14 PM)

After market: 29.81 0 (0%)

29.81

-1.92 (-6.05%)



Find more stocks in the Stock Screener

Follow ChartMill for more